What's Happening?
Experic, a contract development and manufacturing organization (CDMO) and clinical trial supply services company, has announced the appointment of Matthew Mollan, Ph.D., as its new Chief Executive Officer. Dr. Mollan brings over three decades of experience in pharmaceutical development and manufacturing, having previously held leadership roles at Catalent, Aptuit, and Pfizer. At Catalent, he was instrumental in managing a network of development and manufacturing sites, contributing to significant revenue growth and the commercialization of 20 prescription products. Dr. Mollan succeeds David Wood, who is retiring after five years as CEO. Under Wood's leadership, Experic expanded from a single U.S.-based facility to a global organization, achieving
more than threefold revenue growth since 2021. The company is known for its expertise in challenging powders and inhalation products, operating from facilities in New Jersey and Ireland.
Why It's Important?
The appointment of Dr. Mollan as CEO is significant for Experic as it positions the company for further growth and expansion in the biopharmaceutical industry. His extensive experience in scaling pharmaceutical manufacturing operations and his track record of operational excellence align with Experic's goals of enhancing its capabilities and deepening client relationships. This leadership change comes at a time when the demand for innovative pharmaceutical solutions is high, and Experic's ability to deliver high-quality products efficiently is crucial. The company's growth trajectory under Wood's leadership has set a strong foundation, and Dr. Mollan's expertise is expected to drive further advancements, benefiting both the company and its clients in the biopharmaceutical sector.
What's Next?
With Dr. Mollan at the helm, Experic is likely to focus on expanding its service offerings and enhancing its operational capabilities. The company may pursue strategic partnerships and investments to support its growth objectives. Stakeholders, including clients and employees, can expect a continued emphasis on quality and innovation. The transition in leadership is expected to be smooth, with Dr. Mollan building on the strong foundation laid by his predecessor. As the company navigates this new phase, it will be important to monitor how Experic adapts to industry trends and client needs, potentially influencing its market position and competitive edge.
